Valvular Aortic Valve articles

Highlights TCT 2019

TCT 2019 | PCI in Stable CAD. Prior TAVR, with TAVR or Never?

TCT 2019 | PCI in Stable CAD. Prior TAVR, with TAVR or Never?

Courtesy of SBHCI. This interesting study presented at TCT 2019 and simultaneously published in Am J Cardiol tells us PCI in stable coronary artery disease cannot lower risk in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVR). Unless patients are symptomatic, most coronary artery lesions do not need revascularization according to researchers.

Highlights TCT 2019

TCT 2019 | PARTNER 3: Obvious Short-Term Quality of Life Improvement, but What Happens Afterwards?

Courtesy of SBHCI. Patients with severe aortic stenosis and low surgical risk showed decreased mortality, stroke, and heart failure hospitalization at one year with transcatheter aortic valve replacement compared with surgery. Improved quality of life may seem an obvious consequence, but until now that was mere speculation. This work, presented at the TCT 2019 Scientific Sessions

Highlights TCT 2019

TCT 2019 | COAPT Cost Effectiveness: Better Quality of Life and Survival Rate, but Worth It?

Courtesy of SBHCI. The COAPT showed transcatheter repair of the mitral valve using the MitraClip resulted in reduced mortality and hospitalization for cardiac failure and improved quality of life, compared against optimal medical treatment in patients with cardiac failure and moderate to severe functional mitral regurgitation. The cost-effectiveness of this procedure has not been analyzed

Highlights TCT 2019

TCT 2019 | COAPT at 3 Years: MitraClip Reached Functional Mitral Regurgitation Target

Courtesy of SBHCI. Prognosis of patients with cardiac failure who develop secondary mitral regurgitation due to dilation is uncertain.   The COAPT study was carried out in 78 centers across the US and Canada and included patients with moderate to severe mitral regurgitation (3 or 4 crossovers) symptomatic despite optimal medical treatment (OMT).  614 patients were

Highlights TCT 2019

TCT 2019 | STS/ACC TVT Registry: Relationship Between MitraClip Operator Experience and Events

Courtesy of SBHCI. Mitral valve repair with a MitraClip device is a complex procedure that requires that operators develop a series of skills that may be unusual for them, such as analyzing an echocardiography. In this registry, researchers assessed the relationship between operator experience and procedural outcome. Operators were classified into 3 groups: 1 to 25 procedures

Highlights TCT 2019

TCT 2019 | PORTICO: This vs. Any Other Valve Available in the Market

Courtesy of SBHCI. This work, presented at the TCT 2019 Scientific Sessions, showed the 30-day safety and 1-year efficacy of self-expanding prosthesis Portico compared with all valves approved by the US Food and Drug Administration (FDA) for the treatment of patients with severe aortic stenosis and high surgical risk. Between 2014 and 2019, researchers enrolled 750 patients

Highlights TCT 2019

TCT 2019 | SCOPE I: Self-Expanding Valve Acurate Neo Head to Head with Sapien 3

Courtesy of SBHCI. This work, which was presented during the TCT 2019 Scientific Sessions and simultaneously published in the Lancet, randomized patients to the ACURATE Neo prosthesis (n = 373) vs. the SAPIEN 3 (n = 367) in a head-to-head comparison involving 20 European sites. Transfemoral access was used in all patients. The study had a noninferiority design, and its primary

TAVI en bajo riesgo con “cero” mortalidad y “cero” stroke

Very Encouraging Results for TAVR in Low-Risk Patients

Courtesy of Dr. Carlos Fava. About 12% of patients >75 years old have aortic stenosis. In 3%-4% of them, such disease is severe. Transcatheter aortic valve replacement (TAVR) has already proven to be beneficial for extreme-, high-, and intermediate-risk patients. Regarding low-risk patients, we currently have different analyses; two of them are randomized and their results are

TAVR and Pacemakers, New Strategies

Courtesy of Dr. Carlos Fava. TAVR has been shown beneficial and is constantly being advanced onto lower risk populations, but at present, it is limited (perhaps most importantly in aortic tricuspid valves) by the need for permanent pacemaker implantation (PPMI), especially when it comes to self-expandable valves, as the latest study on low risk populations

El reemplazo transcatéter en válvulas bicúspides suma evidencia pero continúan los desafíos

TAVR in Bicuspid Has the Same Results in Surgery at Hospital Level

Courtesy of Dr. Carlos Fava. Bicuspid aortic stenosis patients (bicuspid AS) represent a small group and have not been included in the larger transcatheter aortic valve replacement (TAVR) studies, since they present different morphology and asymmetric calcification, which might come along with more paravalvular leak and less accurate positioning. Between 2012 and 2016, 475,315 patients

La reparación de la válvula mitral con Mitraclip es segura en pacientes de alto riesgo

MitraClip in the Real World: Mid-Term Progress

Courtesy of Dr. Carlos Fava. The fact that the outcomes of edge-to-edge repair with MitraClip have improved, particularly in the immediate and short term, is widely known. Such improvement is basically a result of more operator experience and the arrival of 3-D echocardiography. However, there are no mid-term follow-up studies available, except for the EVEREST